Menopausal Hot Flashes Market Trends

Statistics for the 2023 & 2024 Menopausal Hot Flashes market trends, created by Mordor Intelligence™ Industry Reports. Menopausal Hot Flashes trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Menopausal Hot Flashes Industry

This section covers the major market trends shaping the Menopausal Hot Flashes Market according to our research experts:

Estrogen Segment Expected to Hold Significant Market Share

The estrogen segment is expected to witness significant growth in the overall market over the forecast period. The factors attributing to the market growth are the increasing aging women population along with the rising number of menopausal symptoms as well as increasing product launches.

Estrogen supplements help increase female hormone levels and reduce the symptoms of menopause, including fever. Some of the United States FDA-approved estradiol-containing heat treatments are Alora, Estraderm, Estrogel, Evamist, Vivelle, Climara, Divigel, and Estrace. Some of the benefits associated with estrogen medications include improving the health of the vagina, reducing the symptoms of menopause, and possibly promoting bone and heart health.

The rising burden of menopausal vasomotor symptoms is the key factor driving the demand for hormonal therapy. As per an article published in Frontiers in Endocrinology in March 2021, it was observed that systemic estrogen therapy is the most effective treatment for the relief of troublesome menopausal hot flashes and night sweats. Additionally, it can lessen menopausal vaginal symptoms, such as dryness, itching, burning, and discomfort during sexual activity, as well as vulvovaginal atrophy, including vaginal dryness and dyspareunia. As a result, the estrogen component is essential in the market for menopausal hot flashes and is predicted to exhibit a similar trend during the projected period.

Therefore, due to the high prevalence of menopausal symptoms and the availability of estradiol drugs and related products, the studied segment is expected to grow over the forecast period.

Menopausal Hot Flashes Market - Active Menopausal Hot Flashes Clinical Trials (in Numbers), By Phase, Global, as of November 2022

North America Expected to Hold Significant Market Share

North America is expected to grow in the menopausal hot flashes market due to the increased incidence of menopause, increased awareness of menopause, rising healthcare expenditure, and a large percentage of older women in the region.

According to an article published in the Journal of the North American Menopause Society in August 2021, it has been observed that the prevalence of vasomotor menopausal symptoms was high in the United States. As per the same source, the most common menopausal symptoms were feeling tired or worn out, pain in muscles and joints, difficulty sleeping, and hot flashes. The menopausal hot flashes and night sweats had a more considerable influence on daily activities than on work-related activities. Thus, the high burden of menopausal vasomotor symptoms among women is expected to increase the demand for effective treatment, propelling the market growth.

Additionally, the rising aging women population in the region increases the demand for menopausal drugs and therapies as they experience poor quality of life due to several symptoms during the menopause phase. For instance, as per a research report published by the Menopause Foundation of Canada, in October 2022, about 10 million women living in Canada over the age of 40 years were in their perimenopause, menopause, and postmenopause stage. It has been observed that 84% of the women experienced hot flashes, and 77% were aware of night sweats. In addition, more than two-thirds of the women population was unaware of additional symptoms such as urinary tract infections, heart palpitations, migraines, anxiety, depression, and memory issues.

The rising product launches and approvals from the regulatory authority, as well as growing company activities in conducting clinical trials for treating menopausal symptoms, are also propelling the market growth. As per, as of September 2022, Acer Therapeutics Inc. conducted a Phase II clinical study of ACER-801 (osanetant) to assess its safety and effectiveness in treating moderate to severe Vasomotor Symptoms (VMS). Also, in December 2021, Acer Therapeutics Inc. received United States FDA clearance of its Investigational New Drug (IND) application for its selective non-peptide neurokinin three receptors (NK3R) antagonist, ACER-801 (osanetant) for the potential treatment of induced Vasomotor Symptoms (iVMS).

Furthermore, in May 2021, TherapeuticsMD, Inc. submitted a supplemental New Drug Application for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, a hormone therapy combination of estradiol and progesterone in a single, oral capsule, to the United States FDA.

Thus, owing to the abovementioned factors, such as the high prevalence of vasomotor menopausal symptoms coupled with the aging women population and increasing product launches and company activities, the studied market is expected to grow in the North American region over the forecast period.

Menopausal Hot Flashes Market - Growth Rate by Region

Menopausal Hot Flashes Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)